Posted by Michael Wonder on 26 Oct 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) is available for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
25 October 2023 - Merck and Eisai announced today that Keytruda, an anti-PD-1 therapy, in combination with Lenvima, the multiple receptor tyrosine kinase inhibitor discovered by Eisai, is reimbursed under the Alberta, British Columbia, Nova Scotia, Ontario, Quebec, and Saskatchewan drug plans with respective clinical criteria and conditions for adult patients with advanced (not amenable to curative surgery or radiation) or metastatic renal cell carcinoma, with no prior systemic therapy for metastatic renal cell carcinoma.
This combination therapy was approved by Health Canada in 2022, based on the results from the Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which demonstrated statistically significant improvements in progression-free survival, overall survival, and objective response rate versus sunitinib.
